How growth hormone affects your bones

Bone is living tissue. It is constantly being broken down by cells called osteoclasts and rebuilt by cells called osteoblasts. Growth hormone, largely through its downstream messenger IGF‑1 (insulin‑like growth factor 1), stimulates osteoblast activity and helps regulate the balance between breakdown and formation.[web:771]

When growth hormone is deficient, this balance tips toward net bone loss. Over years, that translates to lower bone mineral density, increased bone fragility, and a higher likelihood of fractures in the hip, spine, and wrist. Clinical reviews of adult growth hormone deficiency consistently show reduced bone mineral density compared with age‑matched controls, especially in long‑standing untreated cases.[web:771][web:770]

A clear real‑world example is the adult who has pituitary surgery for a benign tumor, then quietly loses height and develops back pain over several years. Their DEXA scan shows osteopenia or osteoporosis despite decent calcium intake and activity. When proper endocrine testing eventually confirms adult‑onset growth hormone deficiency, the bone changes are recognized as part of the same untreated process.

What current research shows about bone density

Clinical data on HGH therapy and bone density in adults has been accruing since the 1990s, and the signal is consistent: in adults with confirmed growth hormone deficiency, recombinant human growth hormone therapy can improve bone mineral density when treatment is maintained for at least 18 to 24 months.[web:771][web:779]

The timing is important. Bone responds slowly. Many studies show a small, temporary dip in measured bone density during the first 6 to 12 months of HGH therapy. This reflects accelerated remodeling, where older bone is being cleared before new, stronger bone is fully laid down. After that early phase, bone density tends to rise, with the largest gains typically recorded after 18 months or more of continuous treatment.[web:771]

Recent work on newer long‑acting growth hormone formulations such as lonapegsomatropin (Skytrofa) has focused on body composition and safety, but bone health remains a standard secondary outcome. Long‑term extension data presented in 2026 showed adults with GHD maintained favorable body composition and IGF‑1 normalization on once‑weekly dosing, with bone parameters followed as part of ongoing monitoring.[web:773]

Who is most at risk for GHD‑related bone loss

Not every adult with growth hormone deficiency will experience the same degree of bone loss. Several factors increase skeletal risk:

Duration of deficiency. The longer GHD goes undiagnosed and untreated, the more cumulative the effect on bone. Adults with childhood‑onset GHD that persisted into adulthood without continuous therapy generally show the greatest bone impact on DEXA scan.[web:779]

Sex and hormonal status. Postmenopausal women have a double hit because falling estrogen independently accelerates bone loss. When reduced estrogen is combined with GHD, bone loss tends to progress faster unless both issues are properly treated.[web:770]

Activity level. Weight‑bearing exercise is one of the strongest natural stimulants for bone formation. Sedentary adults with GHD miss that mechanical stimulus and usually see worse bone trends than active adults with the same lab profile.[web:770]

Other pituitary hormone deficiencies. Adults with broader hypopituitarism who also lack thyroid hormone, cortisol, or sex hormones face compounded skeletal risk, because each of those hormones influences bone metabolism independently of growth hormone.[web:776]

How HGH therapy is monitored for bone health

In a properly supervised program, bone health is tracked from the start. Most endocrinologists obtain a baseline DEXA scan of the lumbar spine and hip before starting HGH therapy and repeat it roughly every 12 to 24 months to quantify change. This allows the team to see whether bone mineral density is stabilizing, improving, or continuing to fall.[web:776]

Alongside DEXA, IGF‑1 levels are followed regularly as a surrogate for growth hormone activity. The goal is to keep IGF‑1 in the age‑adjusted normal range, not to push it above normal. Too little HGH has limited effect on bone; too much increases the risk of fluid retention, joint discomfort, and abnormal bone remodeling without proportional benefit.[web:771]

This is why using HGH on your own, without testing or supervision, is risky. Doses used in unsupervised or cosmetic protocols often push IGF‑1 above the normal range for long periods, which does not mimic physiologic replacement and can destabilize the same tissues you are trying to protect.

Why HGH therapy must be part of a broader bone strategy

For adults with documented GHD, HGH therapy is one important piece of a bone‑protection plan, not a standalone solution. Bone is more likely to improve when growth hormone replacement is combined with adequate calcium and vitamin D intake, regular weight‑bearing exercise, limited smoking and alcohol, and, when appropriate, sex hormone replacement.[web:770]

Patients who start HGH but remain sedentary, consume very little calcium, and avoid sun exposure or vitamin D supplementation will almost always see less improvement than those who address all the drivers of bone loss together. In some higher‑risk cases, physicians may also combine HGH with other bone‑specific medications like bisphosphonates or denosumab, depending on fracture risk and DEXA results.[web:770]

Setting realistic expectations for change

If you are considering HGH therapy because of low bone density linked to confirmed GHD, it is important to keep your time horizon realistic. Many patients notice energy and body‑composition changes in the first few months, but bone density usually takes at least 18 to 24 months to show a clear positive trend on DEXA.[web:771]

Low bone density by itself does not prove growth hormone deficiency, but in adults with compatible symptoms and a history of pituitary disease, head trauma, or brain radiation, it is one more red flag that justifies proper endocrine evaluation. A full work‑up typically includes IGF‑1 measurement and at least one formal stimulation test to confirm whether your pituitary can still mount an adequate growth hormone response.[web:776]

If you want a step‑by‑step overview of that evaluation process and how our clinic approaches candidacy, you can read our guide on how to know if you are a candidate for HGH therapy.

For independent, guideline‑level information on adult growth hormone deficiency and bone health, the Endocrine Society publishes evidence‑based clinical practice recommendations that many endocrinologists use as a framework for diagnosis and long‑term management.[web:771]